Your browser doesn't support javascript.
Early cross-coronavirus reactive signatures of humoral immunity against COVID-19.
Kaplonek, Paulina; Wang, Chuangqi; Bartsch, Yannic; Fischinger, Stephanie; Gorman, Matthew J; Bowman, Kathryn; Kang, Jaewon; Dayal, Diana; Martin, Patrick; Nowak, Radoslaw P; Villani, Alexandra-Chloé; Hsieh, Ching-Lin; Charland, Nicole C; Gonye, Anna L K; Gushterova, Irena; Khanna, Hargun K; LaSalle, Thomas J; Lavin-Parsons, Kendall M; Lilley, Brendan M; Lodenstein, Carl L; Manakongtreecheep, Kasidet; Margolin, Justin D; McKaig, Brenna N; Rojas-Lopez, Maricarmen; Russo, Brian C; Sharma, Nihaarika; Tantivit, Jessica; Thomas, Molly F; Sade-Feldman, Moshe; Feldman, Jared; Julg, Boris; Nilles, Eric J; Musk, Elon R; Menon, Anil S; Fischer, Eric S; McLellan, Jason S; Schmidt, Aaron; Goldberg, Marcia B; Filbin, Michael R; Hacohen, Nir; Lauffenburger, Douglas A; Alter, Galit.
  • Kaplonek P; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Wang C; Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA.
  • Bartsch Y; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Fischinger S; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Gorman MJ; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Bowman K; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Kang J; Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA.
  • Dayal D; Space Exploration Technologies Corporation, Hawthorne, CA, USA.
  • Martin P; Space Exploration Technologies Corporation, Hawthorne, CA, USA.
  • Nowak RP; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Villani AC; Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA, USA.
  • Hsieh CL; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
  • Charland NC; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Gonye ALK; Department of Medicine, Harvard Medical School, Boston, MA, USA.
  • Gushterova I; Center for Immunology and Inflammatory Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Khanna HK; Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
  • LaSalle TJ; Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Lavin-Parsons KM; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
  • Lilley BM; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Lodenstein CL; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
  • Manakongtreecheep K; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Margolin JD; Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • McKaig BN; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
  • Rojas-Lopez M; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Russo BC; Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Sharma N; Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Tantivit J; Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Thomas MF; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
  • Sade-Feldman M; Center for Immunology and Inflammatory Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Feldman J; Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Julg B; Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Nilles EJ; Department of Medicine, Harvard Medical School, Boston, MA, USA.
  • Musk ER; Department of Microbiology, Harvard Medical School, Boston, MA, USA.
  • Menon AS; Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Fischer ES; Department of Medicine, Harvard Medical School, Boston, MA, USA.
  • McLellan JS; Department of Microbiology, Harvard Medical School, Boston, MA, USA.
  • Schmidt A; Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Goldberg MB; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
  • Filbin MR; Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Hacohen N; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
  • Lauffenburger DA; Center for Immunology and Inflammatory Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
  • Alter G; Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA.
Sci Immunol ; 6(64): eabj2901, 2021 Oct 15.
Article in English | MEDLINE | ID: covidwho-1470496
ABSTRACT
The introduction of vaccines has inspired hope in the battle against SARS-CoV-2. However, the emergence of viral variants, in the absence of potent antivirals, has left the world struggling with the uncertain nature of this disease. Antibodies currently represent the strongest correlate of immunity against SARS-CoV-2, thus we profiled the earliest humoral signatures in a large cohort of acutely ill (survivors and nonsurvivors) and mild or asymptomatic individuals with COVID-19. Although a SARS-CoV-2­specific immune response evolved rapidly in survivors of COVID-19, nonsurvivors exhibited blunted and delayed humoral immune evolution, particularly with respect to S2-specific antibodies. Given the conservation of S2 across ß-coronaviruses, we found that the early development of SARS-CoV-2­specific immunity occurred in tandem with preexisting common ß-coronavirus OC43 humoral immunity in survivors, which was also selectively expanded in individuals that develop a paucisymptomatic infection. These data point to the importance of cross-coronavirus immunity as a correlate of protection against COVID-19.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Cross Reactions / Immunity, Humoral / SARS-CoV-2 / COVID-19 Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Adolescent / Adult / Humans / Young adult Language: English Journal: Sci Immunol Year: 2021 Document Type: Article Affiliation country: Sciimmunol.abj2901

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Cross Reactions / Immunity, Humoral / SARS-CoV-2 / COVID-19 Type of study: Cohort study / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Adolescent / Adult / Humans / Young adult Language: English Journal: Sci Immunol Year: 2021 Document Type: Article Affiliation country: Sciimmunol.abj2901